Axsome Therapeutics Deal History & Licensing Activity
Axsome Therapeutics is a biotech headquartered in US. Over the past three years, Axsome Therapeutics has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 19 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
3
Active Trials
19
Top Modality
Small Molecules
Focus Area
CNS Disorders
Axsome Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Axsome Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| balipodect | Takeda | Small Molecules | Phase 2 | acquisition | Apr 1, 2026 |
| AZD7325 | Axsome Therapeutics, Inc. | Small Molecules | Phase 1 | license | Nov 6, 2025 |
| BAER-101 (AXS-17, AZD7325) | Avenue Therapeutics / Baergic Bio | Small Molecules | Preclinical | acquisition | Nov 6, 2025 |
Axsome Therapeutics Pipeline Focus
Therapeutic areas and modalities where Axsome Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Axsome Therapeutics Strategic Signals
Key indicators of Axsome Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Axsome Therapeutics Clinical Pipeline
Axsome Therapeutics has 19 active clinical trials across 4 development phases.
6
Unknown
2
Phase 4
1
Phase 2
10
Phase 3
See How Your Asset Matches Axsome Therapeutics's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Axsome Therapeutics Licensing & Deal Activity
Axsome Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Axsome Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Axsome Therapeutics include CNS Disorders (14 deals and trials), and Neurology (6 deals and trials). In terms of modality, Axsome Therapeutics has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Axsome Therapeutics and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Axsome Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.